Our Approach
Understanding the Human immune system to develop more effective therapies
Current drug discovery pipelines are based on reductionist approaches using cell lines, mouse models, or stem-cell derived cell types. Although the “bench to bedside” approach has revolutionized modern medicine, many promising drug candidates routinely fail human clinical trials. The O’Sullivan Lab utilizes an ICE cyclical translation approach using cellular and systems immunology in order to identify novel and more effective treatments for human disease. This consists of 1) Identification of novel pathways using bulk and single cell RNA sequencing (scRNAseq) of clinical samples to study relevant cellular communication and signaling networks 2) CRISPR screening primary human cells to reveal gene regulatory networks in response to activating or inhibitory signals identified from clinical datasets and 3) Engineering primary human innate immune cells using these combined data
